TEM
Tempus AI·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TEM
Tempus Ai, Inc.
A company specializing in artificial intelligence precision medicine.
600 West Chicago Avenue, Suite 510, Chicago, Illinois 60654
--
Founded by Eric Lefkofsky, Tempus AI, Inc., was originally established in Delaware in August 2015 as Bioin LLC. Effective August 7, 2025, the Company was reincorporated from a Delaware corporation into a Nevada corporation by conversion. The company is committed to unlocking the true power of precision medicine by creating intelligent diagnosis through the practical application of artificial intelligence (AI) in healthcare. They personalize the results by making the tests intelligent by connecting the laboratory results with the patient's own clinical data.
Earnings Call
Q1/2025
Estimate EPS-0.27
Actual EPS-0.24
Estimate Revenue248.13M
Actual Revenue255.70M
Tempus Q1 2025: Unpacking Contradictions in Revenue Guidance, Insights Growth, and Market Dynamics
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.25
Actual EPS-0.22
Estimate Revenue297.76M
Actual Revenue314.60M
Tempus AI's Q2 2025 Earnings Call: Unpacking Key Contradictions in Genomics Growth and AI Strategy
Aug 08,2025 11:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TEM has released its 2025 Q3 earnings. EPS was reported at -0.11, versus the expected -0.18, beating expectations. The chart below visualizes how TEM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TEM has released its 2025 Q3 earnings report, with revenue of 334.21M, reflecting a YoY change of 84.72%, and net profit of -79.98M, showing a YoY change of -5.46%. The Sankey diagram below clearly presents TEM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
